Physician profile
Monica E Hoog
NPI 1699230961
$1,851.44
in general payments reported to CMS, 2019-2025
21 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $227 · 2023: $1,157 · 2024: $105 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777 · Travel and Lodging: $676 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.39 |
| Travel and Lodging | $675.74 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,179.88 | 2021-2023 | Synchromedii, Intellis Adaptivestim, Vanta Adaptivestim |
| Boston Scientific Corporation | $126.02 | 2023-2025 | Bodyguardian, Cds Broad Portfolio Offering |
| Intra-Sana Laboratories | $66.46 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Paratek Pharmaceuticals, INC. | $64.11 | 2021-2024 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $56.91 | 2023-2024 | Breztri |
| Glaxosmithkline, LLC. | $53.28 | 2023 | Trelegy Ellipta |
| Ani Pharmaceuticals, INC. | $42.00 | 2025 | Purified Cortrophin Gel |
| Abbvie INC. | $39.25 | 2022 | |
| Allergan, INC. | $37.29 | 2021 | |
| Pfizer INC. | $29.02 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $25.28 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.76 | 2025 | Jardiance |
| Currax Pharmaceuticals LLC | $16.71 | 2022 | |
| Novo Nordisk INC | $16.40 | 2025 | Wegovy |
| Biohaven Pharmaceuticals, INC. | $13.93 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13.17 | 2023 | |
| Astellas Pharma US INC | $12.80 | 2023 | Myrbetriq |
| Pear Therapeutics (US), INC. | $12.45 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.14 | 2022 | |
| Amgen INC. | $11.35 | 2022 | |
| Grt US Holding, INC. | $6.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Hoog listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.